Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Eli Lilly's weight-loss pill wins EU drug regulator's backing

By Reuters News10:24 (UTC), 16 October 2026 Updated

Oct 16 (Reuters) - The European Medicines Agency's committee on Friday recommended approval of Eli Lilly's LLY.N weight-loss pill Foundayo, making it the second oral weight-loss drug to win the agency's backing after Novo Nordisk's NOVOb.CO Wegovy pill.

The European Commission will now review the recommendation and give a final nod before the company can launch the drug. Novo's Wegovy pill won EU approval in July.

The race to broaden access to their oral drugs has become the latest battleground in Novo and Lilly's weight-loss drug rivalry, as both aim to secure a larger share of a market expected to surpass $100 billion by 2030.

The EMA recommended granting a marketing authorisation for Foundayo for weight management and treatment of type 2 diabetes in adults.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.